Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900976 · ClinicalTrials.gov registry record · Phase 2
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
A Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 20
- Study locations
NCT02900976 is a Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder that has completed, run by Children's Oncology Group. The registered enrollment target is 18 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02900976, a Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. LMP-specific T-cells are special immune system cells trained to recognize proteins found on post-transplant lymphoproliferative disorder tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells may work better in treating pediatric organ recipients with post-transplant lymphoproliferative disorder than rituximab alone.
Conditions Studied
Interventions
- BIOLOGICAL Rituximab
- BIOLOGICAL Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mission Bay - San Francisco
Florida
- UF Health Cancer Institute - Gainesville - Gainesville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
- Mayo Clinic in Rochester - Rochester
Alabama
- Children's Hospital of Alabama - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02900976
The ClinicalTrials.gov registry entry for NCT02900976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT02900976 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02900976 about?
NCT02900976 is a clinical study titled "Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder". This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclon...
What is the current status of trial NCT02900976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2017-03-22. Estimated completion is 2025-12-31.
What conditions does trial NCT02900976 study?
This clinical trial studies the following conditions: Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT02900976?
The interventions under investigation include: Rituximab (BIOLOGICAL), Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02900976?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02900976 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
EBV-Related Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.